Strasbourg, France, February 4, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG) a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its financial reporting and Annual shareholders’ meeting dates for 2026:
March 24, 2026: 2025 Fiscal Year Results
April 29, 2026: First Quarter 2026 Financial Results
May 13, 2026: Annual Shareholders’ Meeting
September 24, 2026: First Half 2026 Financial Results
November 9, 2026: Third Quarter 2026 Financial Results
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer